https://european-biotechnology.net/wp-content/uploads/2025/11/Novo-Trump_380460666_eC2ksQPRFWpkTgcwvE5bxK1xc4qVgn7B-e1762502390157.jpg228406Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-11-07 07:59:572025-11-07 07:59:57Eli Lilly and Novo Nordisk slash obesity drug prices
https://european-biotechnology.net/wp-content/uploads/2025/11/AAVantgarde_552298461_-MikeCS-Images-1-1-e1762203895371.jpg233469Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-11-03 21:05:032025-11-03 21:05:03AAVantgarde secures $141m Series B funding
https://european-biotechnology.net/wp-content/uploads/2025/10/Fund_561407813_gxBImUPADGeLd76der57q0VC45cPhSd5-e1761660902697.jpg370967Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-10-28 07:59:402025-10-28 07:59:40GHO Capital expands healthcare reach with €2.5bn Fund IV close
https://european-biotechnology.net/wp-content/uploads/2025/10/Hemab_1760407451_tg-e1761576825745.jpg535957Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-10-27 14:53:532025-10-27 14:53:53Hemab Therapeutics bags US$157m in Series C financing
